Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
A phase 3 trial testing HS-20093 in osteosarcoma, active and no longer recruiting.
Overview
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure is a phase 3 interventional study registered as NCT06935409, led by Hansoh BioMedical R&D, and active but no longer recruiting when checked on 2026-09-11. Official title: A Randomised, Controlled, Open-label, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of HS-20093 for Injection Versus Gemcitabine in Combination With Docetaxel in the Treatment of Osteosarcoma After Previous Second-line Treatment Failure (ARTEMIS-011). Planned enrolment is 117 participants (estimated). The study started in 2025-04-25 and primary completion is expected in 2026-08-31. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Shares Hansoh Pharmaceutical, HS-20093 and the tag ctgov-ingest.
- TrialA Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Shares Hansoh Pharmaceutical and the tag ctgov-ingest.
- TrialHS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Shares Hansoh Pharmaceutical and the tag ctgov-ingest.
- TreatmentHS-20089
Shares Hansoh Pharmaceutical and the tag ctgov-ingest.
- TreatmentHS-20117
Shares Hansoh Pharmaceutical and the tag ctgov-ingest.
- TreatmentCobolimab
Shares Osteosarcoma and the tag ctgov-ingest.